KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Interest Expenses (2019 - 2024)

Historic Interest Expenses for Inovio Pharmaceuticals (INO) over the last 6 years, with Q1 2024 value amounting to $177833.0.

  • Inovio Pharmaceuticals' Interest Expenses fell 4327.28% to $177833.0 in Q1 2024 from the same period last year, while for Dec 2024 it was $177833.0, marking a year-over-year decrease of 8545.68%. This contributed to the annual value of $177833.0 for FY2024, which is 8545.68% down from last year.
  • Inovio Pharmaceuticals' Interest Expenses amounted to $177833.0 in Q1 2024, which was down 4327.28% from $282325.0 recorded in Q4 2023.
  • In the past 5 years, Inovio Pharmaceuticals' Interest Expenses registered a high of $2.8 million during Q2 2020, and its lowest value of $177833.0 during Q1 2024.
  • Its 5-year average for Interest Expenses is $781968.9, with a median of $313488.0 in 2022.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Interest Expenses surged by 32724.02% in 2020 and then crashed by 8360.43% in 2021.
  • Over the past 5 years, Inovio Pharmaceuticals' Interest Expenses (Quarter) stood at $1.1 million in 2020, then crashed by 55.03% to $480313.0 in 2021, then crashed by 34.73% to $313488.0 in 2022, then dropped by 9.94% to $282325.0 in 2023, then tumbled by 37.01% to $177833.0 in 2024.
  • Its Interest Expenses was $177833.0 in Q1 2024, compared to $282325.0 in Q4 2023 and $313488.0 in Q3 2023.